Every year millions of people are affected by postoperative respiratory complications. In US alone, more than 100’000 patients annually are at risk of adverse events associated with undetected residual neuromuscular blockade.
Senzime´s innovative device, TetraGraph, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBA´s).
TetraGraph can be used from start to finish during the surgical procedure and it enables objective assessment of correct dose of medication and helps to determine when the patient is recovered sufficiently to cope with vital spontaneous breathing.
Senzime, Inc. is headquartered in Naples, Florida.
Residual Neuromuscular Blockade
Qualitative vs Quantitative Monitoring
New Gold Standard